Serologicals Corporation to Present at 2005 First Analysis Investment Conference

Serologicals Corporation (NASDAQ:SERO) today announced
that it is scheduled to give an investor presentation at the 2005
First Analysis Investment Conference on November 17, 2005.
   David A. Dodd, President and Chief Executive Officer for
Serologicals Corporation, will be making the presentation, scheduled
for 10:35 a.m. (ET) at The New York Palace Hotel in New York City. The
presentation will be web cast live (audio only) and can be accessed
through the Company's website at www.serologicals.com or at
http://www.wsw.com/webcast/fa3/sero/.
   Serologicals Corporation (NASDAQ:SERO), headquartered in Atlanta,
Georgia, is a global provider of biological products, enabling
technologies and services to a diverse customer base that includes
major life science companies and leading research institutions. Our
customers use our products, technologies and services in a wide
variety of their activities, including basic research, drug discovery,
diagnosis and biomanufacturing. Our products, technologies and
services are essential tools for research in key disciplines,
including neurology, oncology, hematology, immunology, cardiology,
proteomics, infectious diseases, cell signaling and molecular biology.
In addition, the Company is the world's leading provider of monoclonal
antibodies for the blood typing industry.
   Serologicals employs a total of more than 1,000 people worldwide
in three Serologicals' companies: Chemicon International,
headquartered in Temecula, CA, Upstate Group, LLC, headquartered in
Charlottesville, VA. and Celliance Corporation, headquartered in
Atlanta, GA.
   For more information, please visit our website:
www.serologicals.com.
   Serologicals is a registered trademark of Serologicals Royalty
Company.